Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity


Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28th at 12:00 PM ET

HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET.

As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide a corporate overview, business outlook, and discuss the Moleculin opportunity.

A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. 

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
[email protected] 

SOURCE Moleculin Biotech, Inc.


These press releases may also interest you

at 10:07
Integral Hires Five New Principals in Key Areas of Health, Engineering, and Sustainability
Integral Consulting continues to invest in its people and expand across practice areas to meet increasing demands of legal, industrial, and government clients. With five new Principals recently added to our team, we further our commitment to address...

at 10:05
Korea Pavilion Highlights 10 Promising Cybersecurity Companies at RSA Conference 2024
The Korea Trade-Investment Promotion Agency (KOTRA) is proud to host the Korea Pavilion at RSA Conference 2024, showcasing 10 promising Korean cybersecurity companies in collaboration with the Korea Information Security Industry Association (KISIA)....

at 10:05
PKSHA develops advanced Large Language Models in collaboration with Microsoft Japan
PKSHA Technology Inc. (TOKYO:3993) has developed one of the first Japanese-English Large Language Models (LLM) using Retentive Network (RetNet) (*1) in collaboration with Microsoft Japan Co., Ltd. Through this LLM development, PKSHA will further...

at 10:05
Comcast Announces New Xfinity Military Discount Program and $1 Million Commitment to Military-Serving Nonprofits
Today, Comcast Corporation built on its long-standing commitment to veterans, service members, and their families with the introduction of several new initiatives. Timed with National Military Appreciation Month, the company unveiled "The Aviators,"...

at 10:05
Dr. David Rhew, Global Chief Medical Officer & Vice President of Healthcare at Microsoft, to Address Rural and Community Healthcare Professionals at TruBridge National Client Conference
TruBridge, Inc. , a healthcare solutions company, will host their annual National Client Conference, "The Next Step," April 29 - May 2, 2024, in Las Vegas, Nevada. Highlighting the collaboration with TruBridge and their commitment to the...

at 10:03
ControlCase Announces New French-Language Leadership in European Expansion
ControlCase is pleased to announce the addition to our team of Bastien Dugamin, who will be helping to lead the expansion of ControlCase services into the French-speaking diaspora. ControlCase President Mr. Suresh Dadlani shared: "We are excited to...

More news about Science and technology...


News published on and distributed by: